(Q82972196)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Combination therapy in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Devon Conway

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jeffrey A Cohen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

299-308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Emerging Therapies for Relapsing Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Current and future management approaches for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Indictment of the microglia as the villain in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Tumor necrosis factor identified in multiple sclerosis brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Additive effect of the combination of glatiramer acetate and minocycline in a model of MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Mitoxantrone treatment of multiple sclerosis: safety considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Immunosuppression followed by immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Review of mitoxantrone in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Long-term experience with induction treatment regimens in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Uses and abuses of meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

The optic neuritis treatment trial: three-year follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Cladribine: an investigational immunomodulatory agent for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

Remyelinating and neuroprotective treatments in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970007-7

7 January 2021

10.1016/S1474-4422(10)70007-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20170843%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference